Projects
This section presents pharmaceutical projects that are announced from time-to-time around the world.
Merck Invests US$29 million (€28 million) to Open Drug Manufacturing Sites in Germany
Merck plans to invest US$29 million 28 million to open two new GMPgrade mRNA drug substance manufacturing sites in Darmstadt and Hamburg, Germany
MSD Invests US$1.18 billion (€1 billion) to Expand Footprint in Ireland
MSD invests US$118 billion 1 billion to expand its facilities in Dunboyne and Carlow, both situated in Ireland
Astellas Pharma Invests US$352 million (€330 million) in State-of-the-Art Facility in Kerry, Ireland
The stateoftheart facility is planned to span approximately 447 acres in size It will consist of a 3storey building with a total floor area of 17,000 square metres, and the buildings footprint will cover approximately 7,300 square metres
Renaissance Lakewood Expands Laboratory Facilities in New Jersey, USA
Renaissance Lakewood expands the capabilities of quality control sprayparticulate laboratory, along with significant upgrades to their analytical and formulation research and development laboratories in New Jersey, USA
ST Pharm Invests US$110 million to Open New Oligonucleotide Facility in South Korea
ST Pharm invests US$110 million to open new stateoftheart Oligonucleotide facility at Banwol campus, South Korea
Eminence Biotechnology Opens New Manufacturing Facility in China
Eminence Biotechnology opens a new stateoftheart production facility in Suzhou Industrial Park, China
Sherlock Biosciences to Open New Bio manufacturing Facility in UK
Sherlock Biosciences plans to open a new biomanufacturing facility located outside of Cambridge, UK
GeneFab Constructs New Manufacturing Facility in California, USA
GeneFab plans to construct a stateoftheart cGMP facility in California, USA, dedicated to the diverse spectrum of genetic medicines
Becton Dickinson Unveils US$36 million (€34 million) R & D Centre in Dublin, Ireland
BD expands operations with US$43 million 4 million RD Centre in Dublin and US$32 million 30 million investment in Enniscorthy manufacturing plant in Ireland
Catalent Expands its Shiga Site
Catalent expands the services and capabilities to support clinical supply demand for cell and gene therapy development in Shiga, Japan
